Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: Results of a randomized study

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 10, 2004, Pages 1099-1104

  Wilder Smith, C H ^a   Rohss K ^b   Bondarov, P ^b   Hallerback B ^b   Svedberg, L E ^b   Ahlbom, H ^b  

^a GI Physiology Laboratory   (Switzerland)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; PANTOPRAZOLE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG DOSE REGIMEN; DRUG EFFECT; DYSPNEA; FATIGUE; FEMALE; FLATULENCE; HUMAN; ILL DEFINED DISORDER; INJECTION PAIN; MALE; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID SECRETION; STOMACH PH; THORAX PAIN;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CROSS-OVER STUDIES; FEMALE; GASTRIC ACID; HUMANS; HYDROGEN-ION CONCENTRATION; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OMEPRAZOLE; SULFOXIDES; TREATMENT OUTCOME;

EID: 10644282356     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02272.x     Document Type: Article

References (24)

1. DiPalma JA. Management of severe gastroesophageal reflux disease. J Clin Gastroenterol 2001; 32: 19-26.
2. Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9(Suppl. 1): 3-7.
3. Miner PB, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole: a five-way, crossover study. Am J Gastroenterol 2003; 98: 2616-20.
4. Wilder-Smith C, Röhss K, Lundin C, et al. Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg. Gastroenterology 2000; 118: A22 (abstract).
5. Nilsson Pieschl C, Lundin C, Hjalmar M, et al. Esomeprazole 20 mg provides faster and more effective acid control than pantoprazole 20 mg in healthy volunteers. Scand J Gastroenterol 2003; 38(Suppl. 238): A-P3.
6. Armstrong D, Bair D, James C, et al. Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. Aliment Pharmacol Ther 2003; 18: 705-11.
7. Metz DC. Potential uses of intravenous proton pump inhibitors to control gastric acid secretion. Digestion 2000; 62: 73-81.
8. Newton M, Kamm MA, Quigley T, et al. Symptomatic gastroesophageal reflux in acutely hospitalized patients. Dig Dis Sci 1999; 4: 140-8.
9. Memis D, Turan A, Karamanlioglu B, et al. The effect of intravenous pantoprazole and ranitidine for improving preoperative gastric fluid properties in adults undergoing elective surgery. Anesth Analg 2003; 97: 1360-3.
10. Jung R, MacLaren R. Proton-pump inhibitors for stress ulcer prophylaxis in critically ill patients. Ann Pharmacother 2002; 36: 1929-37.
11. Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 2000; 343: 310-6.
12. Green FW Jr, Kaplan MM, Curtis LE, et al. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978; 74: 38-43.
13. Berstad A, et al. Pepsin Secretion. In: Scarpignato, C, Bianchi Porro, G, eds. Clinical Investigation of Gastric Function 1990; 17: 95-102.
14. Röhss K, Bondarov P, Lundin C, et al. Esomeprazole 40 mg administered as a 30-minute intravenous infusion provides the same effective acid control as oral administration in healthy subjects. Gastroenterology 2003; 124(4 Suppl. 1): A-231.
15. Wilder-Smith C, Röhss K, Bondarov P, et al. Esomeprazole 40 mg administered intravenously (i.v.) as a 3-min injection or 30-min infusion provides the same effective acid control in healthy subjects. Gastroenterology 2003; 124(4 Suppl. 1): A-233.
16. Metz DC, Pratha V, Martin P, et al. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: 626-33.
17. Wilder-Smith C, Bondarov P, Hallerbäck B, et al. Esomeprazole 40 mg intravenous provides faster and more effective acid control than pantoprazole 40 mg intravenous after first dose and 5 days. Am J Gastroenterol 2003; 98(9 Suppl.): S25.
18. Wilder-Smith CH, Gennoni MA, Triller J, et al. Is a fluoroscopic verification of the electrode position necessary in ambulatory intragastric pH monitoring? Digestion 1992; 52: 1-5.
19. Labenz J, Keeling N, Eklund S, et al. A comparison of esomeprazole 40 mg once-daily and pantoprazole 40 mg once-daily for the healing of erosive esophagitis. Canadian J Gastroenterol 2004; 18(Suppl. A): Abstract 147.
20. Schneider H, Van Rensburg C, Schmidt S. Esomeprazole 40 mg provides safe and effective healing of erosive esophagitis whether administered as an intravenous (i.v.) injection, an i.v. infusion or orally. Am J Gastroenterol 2003; 98(9 Suppl.): S11.
21. Röhss K, Nilsson-Claar C, Rydholm H, et al. Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg. Gastroenterology 2000; 118: A20.
22. Röhss K, Hasselgren G, Hedenström H. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci 2002; 47: 954-8.
23. Wilder-Smith C, Claar-Nilsson C, Hasselgren G, et al. Esomeprazole 40 mg provides faster and more effective acid control than rabeprazole 20 mg in patients with symptoms of GERD. Am J Gastroenterol 2001; 96(9 Suppl.): S45.
24. Hirschowitz BI. A critical analysis with appropriate controls of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology 1991; 101: 1149-58.